- Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
- Addex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
- Addex Completes $4.2 Million Equity Financing
- Addex Raises $4.2 million in Equity Financing
- Addex Provides Corporate Update and Financial Guidance
- Addex Completes Reduction in Nominal Value of Shares
- Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate
- Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
As of last trade,
Addex Therapeutics Ltd (ADXN:NAQ) traded at 0.8086, 18.91% above the 52 week low of 0.68 set on Sep 29, 2022.
0.68Sep 29 20229.03Oct 07 2021
Markit short selling activity
|Market cap||9.58m USD|
Data delayed at least 15 minutes, as of Oct 07 2022 17:49 BST.